Range Low Price High Price Comment
30 days $60.86 $75.66 Wednesday, 1st May 2024 CYTK stock ended at $63.37. This is 3.34% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 4.70% from a day low at $61.37 to a day high of $64.26.
90 days $60.86 $84.05
52 weeks $25.98 $110.00

Historical Cytokinetics prices

Date Open High Low Close Volume
Oct 31, 2023 $31.64 $36.53 $31.46 $34.86 3 752 475
Oct 30, 2023 $31.82 $32.65 $31.50 $32.09 1 649 466
Oct 27, 2023 $32.10 $32.52 $30.37 $31.74 2 348 434
Oct 26, 2023 $33.03 $33.35 $32.27 $32.41 755 983
Oct 25, 2023 $31.44 $33.01 $31.10 $32.59 1 540 721
Oct 24, 2023 $32.47 $33.10 $31.58 $31.86 959 250
Oct 23, 2023 $32.89 $33.38 $31.88 $31.88 787 728
Oct 20, 2023 $33.33 $34.07 $32.93 $33.11 1 335 731
Oct 19, 2023 $34.43 $34.43 $32.49 $32.81 1 377 226
Oct 18, 2023 $35.18 $35.65 $33.99 $34.30 1 420 480
Oct 17, 2023 $34.44 $36.16 $34.44 $35.38 1 548 823
Oct 16, 2023 $34.06 $35.70 $32.99 $34.65 1 747 363
Oct 13, 2023 $33.42 $35.33 $32.79 $34.21 1 537 827
Oct 12, 2023 $35.89 $35.89 $32.50 $33.39 1 904 167
Oct 11, 2023 $35.14 $36.00 $34.26 $35.95 2 487 358
Oct 10, 2023 $31.79 $35.05 $31.63 $34.87 4 244 363
Oct 09, 2023 $30.85 $31.76 $30.13 $31.70 1 291 248
Oct 06, 2023 $27.34 $31.36 $26.83 $30.60 2 575 720
Oct 05, 2023 $26.95 $27.68 $26.55 $27.47 765 954
Oct 04, 2023 $26.85 $27.33 $25.98 $27.05 1 031 523
Oct 03, 2023 $27.91 $28.12 $26.57 $26.88 969 648
Oct 02, 2023 $29.36 $29.40 $27.56 $27.88 1 344 638
Sep 29, 2023 $31.01 $31.09 $29.25 $29.46 1 689 206
Sep 28, 2023 $29.81 $31.72 $28.96 $30.80 1 566 098
Sep 27, 2023 $30.01 $30.55 $29.71 $29.92 659 001
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT